Abstract: A fluid storage and delivery apparatus may include a fluid container, a first apparatus component, and a housing. One or more support members may be coupled to the housing and configured to secure the first apparatus component physically separate from the fluid container. The first apparatus component may be indirectly coupled to the fluid container by one or more coupling members at least partially defining a fluid passageway between the first apparatus component and the fluid container.

Abstract: A fluid storage and delivery apparatus may include a fluid container, a first apparatus component, and a housing. One or more support members may be coupled to the housing and configured to secure the first apparatus component physically separate from the fluid container. The first apparatus component may be indirectly coupled to the fluid container by one or more coupling members at least partially defining a fluid passageway between the first apparatus component and the fluid container.

Abstract: A fluid storage and delivery apparatus may include a fluid container and a vent valve for releasing fluid from the fluid container. The vent valve may include a vent valve body formed from a single piece, and a vent valve inlet and vent valve outlet coupled to the single-piece vent valve body. The apparatus may also include one or more coupling members at least partially defining a fluid passageway between the vent valve and the fluid container.

Abstract: The invention relates to methods for designing inhibitors of serine/threonine kinases and tyrosine kinases, particularly MAP kinases, through the use of ATP-binding site mutants of those kinases. The methods of this invention take advantage of the fact that the mutant kinases are capable of binding inhibitory compounds of other kinases with greater affinity than the corresponding wild-type kinase. The invention further relates to the mutant kinases themselves and crystallizable co-complexes of the mutant kinase and the inhibitory compound.

Abstract: The invention relates to methods for designing inhibitors of serine/threonine kinases and tyrosine kinases, particularly MAP kinases, through the use of ATP-binding site mutants of those kinases. The methods of this invention take advantage of the fact that the mutant kinases are capable of binding inhibitory compounds of other kinases with greater affinity than the corresponding wild-type kinase. The invention further relates to the mutant kinases themselves and crystallizable co-complexes of the mutant kinase and the inhibitory compound.

Abstract: The invention relates to methods for designing inhibitors of serine/threonine kinases and tyrosine kinases, particularly MAP kinases, through the use of ATP-binding site mutants of those kinases. The methods of this invention take advantage of the fact that the mutant kinases are capable of binding inhibitory compounds of other kinases with greater affinity than the corresponding wild-type kinase. The invention further relates to the mutant kinases themselves and crystallizable co-complexes of the mutant kinase and the inhibitory compound.

Abstract: The invention relates to transgenic non-human animals, embryos and isolated cells therefrom that are heterozygous or homozygous for a mutation in the extracellular signal regulated kinase, Erk5, gene. Such animals, embryos and cells express Erk5 at a reduced level or not at all. Analysis of the homozygous embryos demonstrates a lack of vasculature, indicating that Erk-5 plays a role in angiogenesis. Thus, the present invention also relates to methods for temporarily decreasing or eliminating angiogenesis in a mammal by administering an agent which inhibits Erk-5 expression or Erk-5 activity. And the present invention also relates to methods for increasing angiogenesis in a mammal by administering a functional Erk5 gene.

Abstract: The invention relates to transgenic non-human animals, embryos and isolated cells therefrom that are heterozygous or homozygous for a mutation in the extracellular signal regulated kinase, Erk5, gene. Such animals, embryos and cells express Erk5 at a reduced level or not at all. Analysis of the homozygous embryos demonstrates a lack of vasculature, indicating that Erk-5 plays a role in angiogenesis. Thus, the present invention also relates to methods for temporarily decreasing or eliminating angiogenesis in a mammal by administering an agent which inhibits Erk-5 expression or Erk-5 activity. And the present invention also relates to methods for increasing angiogenesis in a mammal by administering a functional Erk5 gene.

Abstract: This invention relates to the use of butyrate prodrugs derived from lactic acid for treating inflammatory bowel disease. The invention also relates to the use of those prodrugs for the treatment of a chemotherapy-induced mucocutaneous side effect in a patient. The invention further relates to the use of butyrate prodrugs for treating lung, colo-rectal or prostate cancer. And the invention also relates to the use of butyrate prodrugs to treat cystic fibrosis and to enhance the efficiency of gene therapy.

Abstract: The invention relates to methods for designing inhibitors of serine/threonine kinases and tyrosine kinases, particularly MAP kinases, through the use of ATP-binding site mutants of those kinases. The methods of this invention take advantage of the fact that the mutant kinases are capable of binding inhibitory compounds of other kinases with greater affinity than the corresponding wild-type kinase. The invention further relates to the mutant kinases themselves and crystallizable co-complexes of the mutant kinase and the inhibitory compound.